Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Other Accumulated Expenses (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Other Accumulated Expenses for 6 consecutive years, with $74316.0 as the latest value for Q2 2025.

  • On a quarterly basis, Other Accumulated Expenses changed N/A to $74316.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $74316.0, a N/A change, with the full-year FY2024 number at $81000.0, down 21.22% from a year prior.
  • Other Accumulated Expenses was $74316.0 for Q2 2025 at Inhibikase Therapeutics, down from $81000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $3.1 million in Q3 2022 to a low of $100.0 in Q3 2023.
  • A 5-year average of $759658.1 and a median of $77658.0 in 2024 define the central range for Other Accumulated Expenses.
  • Biggest YoY gain for Other Accumulated Expenses was 936.46% in 2023; the steepest drop was 100.0% in 2023.
  • Inhibikase Therapeutics' Other Accumulated Expenses stood at $5127.0 in 2021, then soared by 93.49% to $9920.0 in 2022, then surged by 936.46% to $102817.0 in 2023, then fell by 21.22% to $81000.0 in 2024, then fell by 8.25% to $74316.0 in 2025.
  • Per Business Quant, the three most recent readings for IKT's Other Accumulated Expenses are $74316.0 (Q2 2025), $81000.0 (Q4 2024), and $102817.0 (Q4 2023).